Peptides for neurodivergent brains: what TikTok gets wrong

What did @notdony actually say?

The creator claimed, repeatedly and confidently, that "you will fix your ADHD" by taking Retta, referring to retatrutide, a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 2 trials for obesity and metabolic disease. They walked it back slightly, adding "obviously not a cure" and "not going to fix it forever," but the framing was still: take this peptide, your ADHD symptoms improve, full stop. That is a significant claim to make to a neurodivergent TikTok audience with no sourcing, no caveats about access, legality, or individual variation, and no mention of what "fix" actually means clinically. The video is short, assertive, and light on substance.

Does the science back this up?

Barely, and not in the way the creator implies. There is no published clinical trial examining retatrutide specifically for ADHD. What does exist is a growing body of mechanistic and observational research linking GLP-1 receptor activity to dopaminergic signaling, which is relevant because ADHD involves dysregulation of dopamine pathways. A 2023 review by Blundell et al. in Obesity Reviews noted GLP-1 receptors are expressed in the ventral tegmental area and nucleus accumbens, regions central to reward and attention regulation. Separately, anecdotal and self-reported improvements in focus have been documented among GLP-1 users in metabolic contexts. But anecdote is not mechanism, and mechanism is not clinical outcome. Retatrutide adds glucagon receptor agonism to the GLP-1/GIP combination, and its CNS effects are even less characterized than semaglutide's. Saying it "fixes" ADHD based on available data is a stretch that the current literature does not support.

What did they get wrong (or right)?

Wrong: the word "fix." Even with the partial walk-back, saying "you will fix your ADHD" and then directing everyone with ADHD to "take Retta" is irresponsible. ADHD is a heterogeneous neurodevelopmental condition. No single compound fixes it, and no GLP-1 agonist has been evaluated in an ADHD-specific trial with retatrutide. The creator is generalizing from either personal experience or community reports, neither of which qualifies as evidence.

Partially right: the underlying biological intuition is not crazy. GLP-1 pathways do interact with dopamine systems. Researchers like Holt et al. (2022, Diabetes Care) have noted cognitive and mood-related effects in GLP-1 receptor agonist users. Some ADHD patients on semaglutide or liraglutide have reported improved executive function anecdotally. So the general direction of the hypothesis is worth watching. But a hypothesis worth watching is not a recommendation to take an unapproved investigational peptide.

• Retatrutide is not FDA-approved for any indication as of 2024.
• It is not an approved ADHD treatment.
• Compounded versions exist in gray markets and are not equivalent to trial-grade material.

What should you actually know?

Retatrutide is an investigational compound. Eli Lilly's Phase 2 obesity trial (Jastreboff et al., 2023, NEJM) showed substantial weight loss outcomes, which is why there is community interest. But that trial said nothing about ADHD, attention, or executive function because it was not designed to measure those things. If you are neurodivergent and curious about GLP-1-class peptides and cognition, that is a legitimate area of scientific inquiry. It is not, however, a green light to self-administer a triple agonist peptide without medical oversight.

The risks of unmonitored retatrutide use include nausea, gastroparesis-like symptoms, potential thyroid effects extrapolated from GLP-1 class data, and the real problem of sourcing from unregulated suppliers where purity and dose accuracy are unknown. Anyone telling you a peptide will "fix" a neurodevelopmental condition without a physician involved is skipping several important steps.